ProfileGDS5678 / 1442008_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 31% 30% 31% 29% 31% 30% 30% 31% 31% 30% 47% 31% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7201430
GSM967853U87-EV human glioblastoma xenograft - Control 22.6954531
GSM967854U87-EV human glioblastoma xenograft - Control 32.6896830
GSM967855U87-EV human glioblastoma xenograft - Control 42.655231
GSM967856U87-EV human glioblastoma xenograft - Control 52.6112529
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7865731
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7218230
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6744530
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.676331
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6892831
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6803230
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0656347
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6959131
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.685730